Skip to main content
Drug Injury Lawyer 24/7

Actos® Bladder Cancer Lawsuit - Talk to a Lawyer 

Actos® Lawsuit for Bladder Cancer

On June 15, 2011 the FDA (Food and Drug Administration) released a safety announcement to notify the public that using Takeda Pharmaceutical's diabetes drug Actos (pioglitazone) for more than a year may be associated with an increased risk of bladder cancer. Takeda's Actos will now be required to put in additional information about these increased risks of bladder cancer on the label of the diabetes medication Actos (pioglitazone). Fore more information see Actos Warning of Bladder Cancer by FDA


The FDA's safety warning is in response to a five-year study showing a likely increased risk of bladder cancer along with the use of  Takeda's drug Actos over a long period of time and with larger dosages. A French agency conducted a similar study suggesting an increased risk of bladder cancer with the use of the medication Actos (pioglitazone) which brought these issues to the attention of the FDA. The FDA will continue its study of Actos (pioglitazone) to further evaluate a possible increased risk of bladder cancer from long term Actos usage


FDA Study of Actos® Relation to Bladder Cancer


The FDA conducted a study of Actos' relation to bladder cancer utilizing more than 193,000 diabetes patients. These patients were taking the drug Actos for an average of two years. According to the FDA's findings, "compared to never being exposed to pioglitazone (Actos), a duration of pioglitazone therapy longer than 12 months was associated with a 40% increase in the risk of bladder cancer." Doctors are currently recommended not to prescribe Actos to patients currently suffering from bladder cancer or who have a history of bladder cancer in the family.

French and German Actos® Bladder Cancer Studies

The first concerns that Actos might be related to causing bladder cancer surfaced when studies using rats found that the rats given the drug Actos displayed a higher rate of bladder tumors. The most recent study performed by the FDA, an ongoing 10-year study utilizing more than 200,000 diabetes patients, proposes that the risk of developing bladder cancer rises the longer a patient takes the drug Actos. The findings also suggest that there may be a correlation between higher dosages of Actos and an increased likelihood of bladder cancer.


In June of 2011, France medical officials decided to issue an Actos recall and ordered doctors to cease in prescribing Actos because of the increased possibility of bladder cancer. A French study  of public data implied that there is an increase in the risk of bladder cancer concurrent with the use of Actos. The FDA has failed to recall Actos due to the risks of Actos bladder cancer.


The FDA's warning came merely five days after Actos was pulled from the market in both France and Germany for similar reasons. Actos is part of a class of drugs called thiazolidinediones. The only other member of this class of drugs is Avandia which was recently taken off of United States pharmacy shelves due to it being linked with an increased risk of heart attacks.

What is Actos®?

Actos is a drug produced by the pharmaceutical company Takeda meant to treat type-2 diabetes. In 2008 Takeda's drug Actos (pioglitazone) was the 10th best selling drug in the U.S., with sales over $2.4 billion. Actos is part of the same class of drugs as Avandia (rosiglitazone), which has shown a connection to increased risk of heart problems. Because of the concerns of negative side effects from Avandia, Actos sales have greatly increased recently.

Symptoms of Actos® Bladder Cancer

Studies recently conducted by the FDA and French officials suggest that there may be an increased risk of bladder cancer associated the use of Actos (pioglitazone). Some potential symptoms of bladder cancer as a result of the use of Actos may include some or all of the following:


·         Sensation of needing to urinate without results

·         Pain while urinating

·         Blood found in the urine

·         Frequent urination

Actos® Bladder Cancer Lawsuit

If you or a family member took Takeda Pharmaceutical's drug Actos (pioglitazone) and have developed bladder cancer, we encourage you to contact a pharmaceutical lawyer at our firm immediately. An experienced pharmaceutical products liability lawyer at the Willis Law Firm can discuss with your your legal right in potential lawsuit for Actos Bladder Cancer injuries against the makers of the drug.


We will contact you within 24 hours for a free confidential case review. Contact our law firm immediately so that we may explain the rights and options available to you and your family.


Actos® Cancer Lawsuit - Talk to a Lawyer / Attorney

* indicates a required field
Please fill this field.
Willis Law Firm - Houston, Texas Drug Recall Injury Lawyer



This is an Attorney / Lawyer Advertising Website. It is not a medical information, medical dictionary, medical advice or medical help site. Talk to you own treating Doctor about any questions or concerns that you have concerning any medicine, drug, medical device or treatment plan. Do not rely on any information on this site to alter, stop or change any medication or treatment plan by your prescribing or treating Doctor. Many of the drugs and devices listed here on this site have published risk and warnings associated with their use and have not been recalled. This website is not in anyway connected with any drug company or the FDA.Check with your Doctor, Pharmacy and/or the FDA as to any concerns as to their use, recall status and safety. See FDA for the latest information.

Principal Office -Willis Law Firm 5005 Riverway Drive, Suite #160 Houston, Texas 77056